With a new startup, ARCH and Takeda wade into growing search for a Swiss Army knife RNA drug
ARCH and Takeda are stepping — if not quite leaping — into one of the hottest new areas in RNA drug development: tRNA.
On Wednesday the prominent VC firm and the Japanese pharma, along with tech-oriented 8VC, announced a $24 million investment in hC Bioscience, a new startup that will try to use this once-overlooked corner of genetic machinery to develop treatments for rare diseases and cancer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.